1. Teva Pharmaceutical Industries’ Erez Vigodman stepped down as CEO, and the drugmaker said that chairman Yitzhak Peterburg will serve as its interim CEO. Vigodman departs after a series of setbacks in his three-year term, including delayed drug launches and costly acquisitions. (Fortune)

2. Mylan will pay $96.5 million to settle claims that it paid to delay the launch of Cephalon’s generic version of narcolepsy drug Provigil. (Bloomberg)

3. Merck filed for FDA approval of its immunotherapy Keytruda as a treatment for first- and second-line bladder cancer. The therapy competes with Bristol-Myers Squibb’s Opdivo and Roche’s Tecentriq. (PMLive)

4. Cellectis will begin Phase-I trials of its experimental gene edited cell therapy, UCART123, as a treatment for blood cancers. Novartis, Kite Pharma, and Juno Therapeutics are also developing treatments that use modified T cells. (Reuters)

5. Lirilumab, a leukemia drug developed by Bristol-Myers Squibb and Innate Pharma, failed to demonstrate improvement in patients’ leukemia-free survival compared to a placebo in a mid-stage trial. (BioPharma Dive)